^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1d
    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting | N=118 --> 20
    Enrollment closed • Enrollment change
    |
    AZD0120
    6d
    Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis (clinicaltrials.gov)
    P1, N=30, Recruiting, Beijing Boren Hospital
    New P1 trial
    8d
    Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Zhongshan Hospital (Xiamen), Fudan University
    New P1 trial
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    cyclophosphamide • fludarabine IV
    8d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB | N=38 --> 153
    Enrollment change
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    9d
    Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients (clinicaltrials.gov)
    P1, N=18, Recruiting, RenJi Hospital | Trial completion date: May 2025 --> Jun 2029 | Trial primary completion date: Nov 2023 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    AZD0120
    13d
    BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Guangzhou Bio-gene Technology Co., Ltd | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    13d
    UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=0, Withdrawn, The Affiliated Hospital of Xuzhou Medical University | N=15 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide
    14d
    BG-CT-24-015: Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Guangzhou Bio-gene Technology Co., Ltd | N=10 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    21d
    β-hydroxybutyrate potentiates anti-tumor immunity by modulating cytotoxic CD8+ T cell responses. (PubMed, Cancer Immunol Immunother)
    Knockdown of either Tcf7 or Hcar2 in CD8+ T cells abolishes the promoting effect of βOHB on CD8+ T function. Our findings elucidate a metabolite-immune axis that directly regulates the functional state of tumor-infiltrating CD8⁺ T cells and provide experimental evidence linking ketone metabolism to anti-tumor immune regulation.
    Journal
    |
    CD8 (cluster of differentiation 8) • TCF7 (Transcription Factor 7)
    22d
    CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Nanjing Bioheng Biotech Co., Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    27d
    CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease (clinicaltrials.gov)
    P1, N=15, Recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    28d
    IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial